European site enrollment concerns grow to 85% Over the course of just one week, US clinical research study sites’ concern about COVID-19-related interruptions to recruitment and retention has increased by 124%, jumping from 25% to 56% according to an ongoing...
Trial also achieves statistical significance in key secondary endpoints Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway Company to host investor conference call today at 8:30 a.m. EDT GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE)...
ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020. We have now completed the...
EDMONTON, March 24, 2020 /PRNewswire/ – OncoQuest Inc. (“OncoQuest” or the “Company”), a privately held, cancer immunotherapy company today announced the publication of two reports relating to the recently completed Phase 2 trial...
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College...
Email
Text